Thermo Fisher Scientific Inc. $TMO is Nexus Investment Management ULC’s 9th Largest Position

Nexus Investment Management ULC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.5% during the third quarter, Holdings Channel reports. The fund owned 67,537 shares of the medical research company’s stock after purchasing an additional 7,510 shares during the quarter. Thermo Fisher Scientific accounts for 4.7% of Nexus Investment Management ULC’s investment portfolio, making the stock its 9th largest holding. Nexus Investment Management ULC’s holdings in Thermo Fisher Scientific were worth $32,757,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the business. Elevation Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 35.1% in the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after buying an additional 20 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares in the last quarter. S.A. Mason LLC increased its position in shares of Thermo Fisher Scientific by 7.0% in the 3rd quarter. S.A. Mason LLC now owns 319 shares of the medical research company’s stock worth $155,000 after purchasing an additional 21 shares during the last quarter. Lafayette Investments Inc. lifted its position in shares of Thermo Fisher Scientific by 2.4% during the second quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock worth $376,000 after purchasing an additional 22 shares during the last quarter. Finally, Diversified Enterprises LLC grew its position in shares of Thermo Fisher Scientific by 1.6% in the 3rd quarter. Diversified Enterprises LLC now owns 1,411 shares of the medical research company’s stock worth $684,000 after acquiring an additional 22 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TMO. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Barclays upped their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Leerink Partners upped their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $625.47.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $619.14 on Monday. The firm has a market capitalization of $232.62 billion, a PE ratio of 35.77, a P/E/G ratio of 4.07 and a beta of 0.91. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $628.08. The company’s 50 day simple moving average is $581.35 and its 200 day simple moving average is $518.09.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same period last year, the company posted $5.28 EPS. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Insiders Place Their Bets

In related news, VP Lisa P. Britt sold 1,058 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the sale, the vice president directly owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Frederick M. Lowery sold 6,912 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the completion of the transaction, the executive vice president owned 14,367 shares in the company, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 149,271 shares of company stock worth $86,507,282. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.